Metaanalysis of short course antibiotic treatment for group A streptococcal tonsillopharyngitis

Pediatric Infectious Disease Journal

Volumn 24, Issue 10, 2005, Pages 909-917

  Casey, Janet R ^a   Pichichero, Michael E ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Cephalosporins; Group A streptococci; Macrolides; Metaanalysis; Penicillin; Tonsillopharyngitis

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFADROXIL; CEFDINIR; CEFIXIME; CEFOTIAM; CEFPODOXIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; ERYTHROMYCIN ESTOLATE; JOSAMYCIN; MACROLIDE; PENICILLIN DERIVATIVE; TELITHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATION; BIBLIOGRAPHIC DATABASE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; EMBASE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; MEDLINE; META ANALYSIS; NONHUMAN; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PHARYNGITIS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SHORT COURSE THERAPY; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PNEUMONIAE; SYMPTOM; SYSTEMATIC REVIEW; THROAT CULTURE; TONSILLITIS; TONSILLOPHARYNGITIS;

EID: 26944476232     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000180573.21718.36     Document Type: Article

References (51)

1. McCraig LF, Besser RE, Hughes JM. Trends in antimicrobial prescribing rates for children and adolescents. JAMA. 2002;287:3096-3102.
2. Denny FW, Wannamaker LW, Brink WR, Rammelkamp CH Jr, Custer EA. Prevention of rheumatic fever. JAMA. 1950;143:151-153.
3. Wannamaker LW, Rammelkamp CH Jr, Denny FW, et al. Prophylaxis of acute rheumatic fever by treatment of the preceding streptococcal infection with various amounts of depot penicillin. Am J Med. 1951;10: 673-395.
4. Wannamaker LW, Denny FW, Perry WD, et al. The effect of penicillin prophylaxis on streptococcal disease rates and the carrier state. N Engl J Med. 1953;249:1-7.
5. Breese BB. Treatment of β-hemolytic streptococcic infections in the home. JAMA. 1953;152:10-14.
6. Mohler DN, Wallin DG, Dreyfus EG. Studies in the home treatment of streptococcal disease, I: failure of patients to take penicillin by mouth as prescribed. N Engl J Med. 1955;252:1116-1118.
7. Bergman AB, Werner RJ. Failure of children to receive penicillin by mouth. N Engl J Med. 1963;268:1334-1338.
8. Leistyna JA, Macaulay JC. Therapy of streptococcal infections: do pediatric patients receive prescribed oral medication? Am J Dis Child. 1966;111:22-26.
9. Charney E, Bynum R, Eldredge D, et al. How well do patients take oral penicillin? A collaborative study in private practice. Pediatrics. 1967; 40:188-195.
10. Green JL, Ray SP, Charney E. Recurrence rate of streptococcal pharyngitis related to oral penicillin. J Pediatr. 1969;75:292-294.
11. Schwartz RH, Rodriquez WJ, Grundfast KM. Pharmacologie compliance with antibiotic therapy for acute otitis media: influence on subsequent middle ear effusion. Pediatrics. 1981;68:619-622.
12. Finney JW, Friman PC, Rapoff MA, Christophersen ER. Improving compliance with antibiotic regimens for otitis media. Am J Dis Child. 1985;139:89-95.
13. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
14. Peto R, Collins R, Gray R. Large-scale randomized evidence: Large, simple trials and overviews of trials. J Clin Epidemiol. 1995;48:23-40.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
16. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ. 1994;309:1351-1355.
17. Deeks JJ, Altman DG, Bradburn MJ. Fifteen statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith G, Attman D, eds. Systematic Reviews in Health Care. 2nd ed. Oxford, United Kingdom: Blackwell BMJ Books; 2001:285-312.
18. Portier H, Chavanet P, Gouyan JB, Guetar F. Five day treatment of pharyngotonsillitis with cefpodoxime proxetil. J Antimicrob Chemother. 1990;26(suppl E):79-85.
19. Gehanno P, Chiche E. Traitement des angines a streptocoque β hemolytique du groupe A par le cefuroxime axetil pendant 4 jours: etude comparative a la penicilline V pendant 10 jours. Med Mal Infect. 1991;21:66-70.
20. Milatovic D. Evaluation of cefadroxil, penicillin, and erythromycin in the treatment of streptococcal tonsillopharyngitis. Pediatr Infect Dis J. 1991;10:S61-S63.
21. Portier H, Chavanet P, Waldner-Combernoux A, et al. Five versus ten days treatment of streptococcal pharyngotonsillitis: a randomized controlled trial comparing cefpodoxime proxetil and phenoxymethyl penicillin. Scand J Infect Dis. 1994;26:59-66.
22. Pichichero ME, Gooch WM, Rodriguez M, et al. Effective short-course treatment of acute group A β-hemolytic streptococcal tonsillopharyngitis. Arch Pediatr Adolesc Med. 1994;148:1053-1060.
23. Peyramond D, Tigaud S, Bremard-Oury C, Scheimberg A. Multicenter comparative trial of cefixime and phenoxymethylpenicillin for group A β-hemolytic streptococcal tonsillitis. Curr Ther Res. 1994;55(A):14-21.
24. Aujard Y, Boucot I, Brahimi N, Chiche D, Bingen E. Comparative efficacy and safety of four-day cefuroxime axetil and ten-day penicillin treatment of group A β-hemolytic streptococcal pharyngitis in children. Pediatr Infect Dis J. 1995;14:295-300.
25. Carbon C, Chatelin A, Bingen E, et al. A double-blind randomized trial comparing the efficacy and safety of a 5-day course of cefotiam hexetil with that of a 10-day course of penicillin V in adult patients with pharyngitis caused by group A β-haemolvtic streptococci. J Antimicrob Chemother. 1995;35:843-854.
26. Adam D, Group Cefixime Study, Hostalk U, Troster K. Five-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: comparison with 10-day penicillin V therapy. Infection. 1995;23(suppl 2):S83-S86.
27. Tack KJ, Henry DC, Gooch WM, et al. Five-day cefdinir treatment of streptococcal pharyngitis. Antimicrob Agents Chemother. 1998;42:1073-1075.
28. Adam D, Scholz H, Helmerking M. Comparison of short-course (5 day) cefuroxime axetil with a standard 10 day oral penicillin V regimen in the treatment of tonsillopharyngitis. J Antimicrob Chemother. 2000;45: 23-30.
29. Tack KJ, Hedrick JA, Rothstein E, et al. A study of 5-day cefdinir treatment for streptococcal pharyngitis in children. Arch Pediatr Adolesc Med. 1997;151:45-49.
30. Esposito S, Noviello S, Iannielo F, D'Errico G. Short-course therapy with cefaclor for treatment of streptococcal pharyngotonsillitis. Int J Antimicrob Agents. 2001;18:341-345.
31. Mehra S, VanMoerkerke M, Melck J, et al. Short course therapy with cefuroxime axetil for group A streptococcal tonsillopharyngitis in children. Pediatr Infect Dis J. 1998;17:452-457.
32. Portier H, Lucht F, Lescale O, et al. Josamycine 5 jours versus penicilline V 10 jours dans le traitement des angines aigues a streptocoque β-hemolytique du groupe A. Med Mal Infect. 1995;25:1005-1010.
33. Adam D, Scholz H, Pharyngitis Study Group. Five days of erythromycin estolate versus ten days of penicillin V in the treatment of group A streptococcal tonsillopharyngitis in children. Eur J Clin Microbiol Infect Dis. 1996;15:712-717.
34. Portier H, Filipecki J, Weber F, et al. Five day clarithromycin modified release versus 10 day penicillin V for group A streptococcal pharyngitis: a multi-centre, open-label, randomized study. J Antimicrob Chemother. 2002;49:337-344.
35. Norrby SR, Rabie WJ, Bacart P, et al. Efficacy of short-course therapy with the ketolide telithromycin compared with 10 days of penicillin V for the treatment of pharyngitis/tonsillitis. Scand J Infect Dis. 2002;33: 883-890.
36. Takker U, Dzyublyk O, Busman T, Notario G. Comparison of 5 days of extended-release clarithromycin versus 10 days of penicillin V for the treatment of streptococcal pharyngitis/tonsillitis: results of a multicenter, double-blind, randomized study in adolescent and adult patients. Curr Med Res Opin. 2003;19:421-429.
37. Syrogiannopoulos GA, Bozdogan B, Grivea IN, et al. Two dosages of clarithromycin for five days, amoxicillin/clavulanate for five days or penicillin V for ten days in acute group A streptococcal tonsillopharyngitis. Pediatr Infect Dis J. 2004;23:857-865.
38. Gerber MA, Randolph MF, Chanatry J, et al. Five vs. ten days of penicillin V therapy for streptococcal pharyngitis. Am J Dis Child. 1987;141:224-227.
39. Stromberg A, Schwan A, Cars O. Five versus ten days treatment of group A streptococcal pharyngotonsillitis: a randomized controlled clinical trial with phenoxymethyl-penicillin and cefadroxil. Scand J Infect Dis. 1988;20:37-46.
40. Clamorange French Study Group. Peyramond D, Portier H, Geslina P, Cohen R, Six-day amoxicillin versus 10-day penicillin V for group A β-haemolytic streptococcal acute tonsillitis in adults: a French multicentre, open-label, randomized study. Scand J Infect Dis. 1996;28:497-501.
41. Cohen R, Levy C, Doit C, et al. Six-day amoxicillin vs. ten-day penicillin V therapy for group A streptococcal tonsillopharyngitis. Pediatr Infect Dis J. 1996;15:678-682.
42. Casey JR, Pichichero ME. Higher dosages of azithromycin are more effective in group A streptococcal tonsillopharyngitis treatment. Clin Infect Dis. 2005;40:1748-1755.
43. Kozyrskyj AL, Hildes-Ripstein E, Longstaffe SEA, et al. Treatment of acute otitis media with a shortened course of antibiotics: a meta-analysis. JAMA. 1998;279:1736-1742.
44. Gooch WM, Blair E, Puopolo A, et al. Effectiveness of five days of therapy with cefuroxime axetil suspension for treatment of acute otitis media. Pediatr Infect Dis J. 1996;15:157-164.
45. Gehanno P, Taillebe M, Denis P, al et. Short course cefotaxime compared with 5-day co-amoxyclav in acute otitis media in children. J Antimicrob Chemother. 1990;26(suppl A):29-36.
46. Guillemot D, Carbon C, Balkau B, Geslin P, Lecoeur H, et al. Low dosage and long treatment duration of β-lactam: risk factors for carriage of penicillin resistant Streptococcus pneumoniae. JAMA. 1998;279:365-370.
47. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports from meta-analyses of randomized controlled trials: the QUOROM statement. Lancet. 1999;354:1896-1900.
48. Moher D, Pham B, Jones A, et al. Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352:609-613.
49. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by simple, graphical test. BMJ. 1997;315:629-634.
50. Schultz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408-412.
51. Casey JR, Pichichero ME. In: Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30-November 2, 2004, Washington, DC. Washington, DC: American Society for Microbiology; 2004.